Abbvie, Inc. (ABBV) Tops Q2 EPS by 6c; Guides Q3 EPS to Strong Side
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
UPDATE: UBS Upgrades Abbvie (ABBV) to Buy
July 28, 2014 8:14 AM EDT(Updated - July 28, 2014 10:40 AM EDT)
UBS upgraded Abbvie (NYSE: ABBV) from Neutral to Buy with a price target of $67 (from $57). Analyst Marc Goodman noted compelling risk/reward.
"Upgrading ABBV to a Buy rating and PT of $67 with 4-fold investment thesis (1) We like the Shire deal. It's accretive, diversifies earnings... More
